Cofactor Genomics
Cofactor Genomics is a commercial-stage molecular diagnostics company that uses RNA sequencing and proprietary machine learning to predict cancer patient response to immunotherapy, serving oncologists, pathologists, and healthcare systems through its CAP-accredited OncoPrism test.
- Company typePrivate
- Founded2008
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Cofactor Genomics does
Cofactor Genomics is a commercial-stage molecular diagnostics company that builds RNA-based predictive tests to match cancer patients to immunotherapy. Its flagship product, OncoPrism, uses multidimensional biomarkers derived from tumor RNA sequencing combined with proprietary machine learning models (Health Expression Models and Predictive Immune Modeling) to predict patient response to immune checkpoint inhibitors — addressing the well-documented failure mode of PD-L1 IHC, where a large majority of treated patients do not benefit. Validated indications include non-small cell lung cancer (OncoPrism-NSCLC) and head and neck squamous cell carcinoma (OncoPrism-HNSCC), with a diagnostic pipeline covering 11 solid tumor cancers.
The underlying technology is anchored by the PREDAPT clinical trial (NCT04510129), which enrolled patients across 24+ U.S. healthcare systems and generated the roughly 1,500-sample dataset that trains the company's Predictive Immune Modeling platform. The company operates a CAP-accredited clinical laboratory in St. Louis, holds HIPAA-covered clinical operations, and is headquartered in San Francisco as a Delaware C-corp. Cofactor also offers research-use products (ImmunoPrism assay, ActiveSite bioinformatics platform, spike-in RNA controls) that generate adjacent revenue and reinforce the clinical product.
Cofactor makes money by performing OncoPrism tests in its CAP-certified laboratory, with samples shipped from ordering oncologists and pathologists at partner health systems. Medicare national coverage from Palmetto GBA was obtained in October 2024, enabling direct Medicare billing and materially expanding the addressable patient population. The December 2025 strategic investment from Labcorp and Ascension Ventures is earmarked to accelerate commercial rollout across U.S. cancer care networks. Go-to-market is enterprise-focused, targeting medical oncologists, pathologists, and healthcare systems, supported by named institutional partners including Mayo Clinic, Cleveland Clinic, Stanford, Johns Hopkins, and Intermountain Health.
Cofactor Genomics firmographics
Firmographics- Name
- Cofactor Genomics
- Legal name
- Cofactor Genomics, Inc.
- Website
- https://cofactorgenomics.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cofactor Genomics is a commercial-stage molecular diagnostics company that uses RNA sequencing and proprietary machine learning to predict cancer patient response to immunotherapy, serving oncologists, pathologists, and healthcare systems through its CAP-accredited OncoPrism test.
- Ownership category
- akta.pro rank
Cofactor Genomics industry classification
Industry- Product category
- Clinical Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industries
- Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where Cofactor Genomics is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Cofactor Genomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Diagnostic Laboratory Services: Cofactor Genomics operates a CAP-certified clinical diagnostic laboratory offering OncoPrism and ImmunoPrism tests. Revenue is generated through diagnostic testing services billed to healthcare providers, hospitals, and insurance companies including Medicare (Palmetto GBA national coverage). The company disclosed Medicare coverage for OncoPrism as a key milestone enabling broader commercial adoption.
- Clinical Trial Services: The company conducts sponsored clinical trials and research studies with healthcare system partners. The PREDAPT trial (NCT04510129) involves partnerships with 24 healthcare systems studying 11 solid tumor cancers. This provides clinical validation data while building relationships with potential commercial customers.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Cofactor Genomics product offering
Product offeringCore offering
Cofactor Genomics operates a CAP-certified clinical diagnostic laboratory that performs RNA-based predictive diagnostic tests, principally the OncoPrism family (OncoPrism-NSCLC and OncoPrism-HNSCC), which use multidimensional biomarkers and machine learning to predict cancer patient response to immunotherapy before treatment decisions. The company's offering is anchored by a proprietary Health Expression Models database of immune cell gene expression profiles and validated through the PREDAPT clinical trial across 11 solid tumor indications with 24+ healthcare system partners.
Product overview
Cofactor Genomics is a commercial-stage RNA-based predictive diagnostics company. The core product is the OncoPrism® family of tests, which use multidimensional RNA biomarkers and machine learning to predict cancer patient response to immunotherapy. OncoPrism-NSCLC and OncoPrism-HNSCC are specific cancer-type validated tests. Supporting the clinical diagnostics is the research-use ImmunoPrism™ assay for immune profiling. The company also provides RNA-seq services with bioinformatics through the ActiveSite platform, built on a database of Health Expression Models. The PREDAPT clinical trial validates the platform across 11 solid tumor cancers.
Differentiator
Problem solved
Functional benefit
Brands
- OncoPrism: RNA-based predictive diagnostic platform for predicting immunotherapy response in cancer patients
- OncoPrism-NSCLC
- OncoPrism-HNSCC
- ActiveSite
- ImmunoPrism
Products and services
- OncoPrism Immunotherapy Diagnostic RNA-based predictive diagnostic test that uses multidimensional biomarkers and machine learning to predict cancer patient response to immunotherapy before treatment. Indication-specific validated sub-tests include OncoPrism-NSCLC for non-small cell lung cancer and OncoPrism-HNSCC for head and neck squamous cell carcinoma, with a pipeline covering 11 solid tumor indications. Performed in Cofactor's CAP-certified clinical diagnostic laboratory with results returned to ordering physicians, supported by Medicare national coverage.
- ImmunoPrism Research Use Assay RNA-based immune profiling assay that estimates the abundance of eight immune cell types, measures expression of immune-relevant genes such as PD-1 and CTLA-4, and uses Predictive Immune Modeling to classify patients. Available as Research Use Only or as a CAP-validated assay for research applications in immuno-oncology.
- ActiveSite Bioinformatics Platform Web-based bioinformatics interface providing project tracking, quality metrics, and data discovery for RNA sequencing projects. Includes saturation curves for every sample showing performance, gene expression levels, and outlier identification, with automated reporting on sequencing depth requirements and questionable samples to exclude from comparison.
Companies that use Cofactor Genomics
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
Cofactor Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature8 records
Cofactor Genomics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and major.
- Culmination BiocorePartnership with Intermountain Health spinout Culmination Bio to leverage samples and data from one of the largest biobanks in the country to fuel development of OncoPrism test in 11 cancers. Cofactor is 'moving aggressively' to advance the test with Culmination Bio's extensive biobank resources.
- 24 Healthcare Systems (PREDAPT Trial)coreNational PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) Trial (NCT04510129) evaluating OncoPrism assay with 24+ healthcare system partners studying 11 solid tumor cancers.
- Intermountain HealthcorePartner healthcare system in PREDAPT clinical trial and collaboration with spinout Culmination Bio leveraging extensive biobank samples and data for precision medicine clinical trial.
- Cleveland ClinicmajorListed as a client and partner working with Cofactor on clinical validation of OncoPrism diagnostics.
- Mayo ClinicmajorListed as a client and partner working with Cofactor on clinical validation of OncoPrism diagnostics.
- Stanford UniversitymajorAcademic medical center partner listed as working with Cofactor on clinical validation activities.
- Johns Hopkins UniversitymajorAcademic medical center partner listed as working with Cofactor on clinical validation activities.
- UC San DiegomajorAcademic medical center partner listed as working with Cofactor on clinical validation activities.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Cofactor Genomics competitors and assessment
Company assessmentDirect peers
- Oncocyte: Commercial-stage molecular diagnostics company developing tests to inform immunotherapy treatment decisions (e.g., DetermaIO), making it the most directly comparable peer to Cofactor's OncoPrism in the RNA-based IO response prediction space.
- Personalis: Cancer genomics company offering NeXT Personal, an ultra-sensitive tumor-informed liquid biopsy and molecular profiling assay. Comparable NGS-based oncology diagnostics player with similar business model of selling molecular tests to oncologists and pharma partners.
- Caris Life Sciences: Molecular profiling company offering MI Profile and other comprehensive tumor profiling tests that inform treatment selection, including for immunotherapy. Directly comparable as a comprehensive RNA/DNA-based molecular diagnostic platform for oncology treatment guidance.
- NanoString Technologies (Bruker): RNA-based spatial biology and gene expression company with GeoMx Digital Spatial Profiling and nCounter platforms — directly comparable to Cofactor in RNA-based immune profiling technology and immuno-oncology biomarker development.
- Adaptive Biotechnologies: Immune profiling company leveraging sequencing and ML to characterize immune responses, with clonoSEQ for MRD and immunoSEQ for immune repertoire. Comparable in applying sequencing + machine learning to immune-related oncology diagnostics.
Broad incumbents
- Guardant Health: Leading liquid biopsy and oncology precision medicine company offering Guardant360 and Reveal tests. Broader incumbent in oncology molecular diagnostics with much larger commercial footprint, overlapping in immuno-oncology patient stratification.
- Foundation Medicine (Roche): Comprehensive genomic profiling leader (FoundationOne CDx, FoundationOne Liquid CDx) used to guide targeted and immunotherapy treatment selection. Large incumbent with established oncology relationships overlapping with OncoPrism's use case.
- Natera: Oncology and reproductive health diagnostics company with Signatera MRD test and growing oncology franchise. Comparable in commercial-stage molecular diagnostics sold to oncologists through similar reimbursement-driven channels.
- NeoGenomics: Oncology-focused reference laboratory providing comprehensive molecular and biomarker testing services to community oncologists. Comparable business model as a CAP-certified oncology diagnostic lab with established hospital and oncologist relationships.
- Exact Sciences: Large-scale molecular diagnostics company with Oncotype DX and growing oncology franchise (OncoExTra, Cologuard). Comparable as an established molecular diagnostics company pursuing multi-indication oncology testing with Medicare reimbursement.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Cofactor Genomics social profiles
Digital presenceCofactor Genomics compliance and trust
Trust signalCompliance2 records
Cofactor Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cofactor Genomics leadership team
Management profileNumber of profiles
Profiles8 records
Cofactor Genomics funding detail
Funding detailFunding overview
Funding rounds9 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cofactor Genomics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cofactor Genomics
What does Cofactor Genomics do?
Cofactor Genomics operates a CAP-certified clinical diagnostic laboratory that performs RNA-based predictive diagnostic tests, principally the OncoPrism family (OncoPrism-NSCLC and OncoPrism-HNSCC), which use multidimensional biomarkers and machine learning to predict cancer patient response to immunotherapy before treatment decisions. The company's offering is anchored by a proprietary Health Expression Models database of immune cell gene expression profiles and validated through the PREDAPT clinical trial across 11 solid tumor indications with 24+ healthcare system partners.
Is Cofactor Genomics a public or private company?
Cofactor Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cofactor Genomics founded?
Cofactor Genomics was founded in 2008. It employs 11 to 50 people.
Where is Cofactor Genomics based?
Cofactor Genomics is headquartered in San Francisco, United States, in the North America region.
How does Cofactor Genomics make money?
Two revenue lines are on record. Diagnostic Laboratory Services are the primary driver. The others are clinical Trial Services.
Who are Cofactor Genomics's main competitors?
Direct peers on record are Oncocyte, Personalis, Caris Life Sciences, NanoString Technologies (Bruker) and Adaptive Biotechnologies. Broad incumbents are Guardant Health, Foundation Medicine (Roche), Natera, NeoGenomics and Exact Sciences.
Does Cofactor Genomics have an API?
No public API is recorded for Cofactor Genomics.
What industry is Cofactor Genomics in?
Cofactor Genomics's product category is Clinical Molecular Diagnostics. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 621511 and its SIC code is 8071.